China Medical GatewayLoading your healthcare gateway…

Leukemia in China

Overview

Leukemia is a cancer of blood-forming cells in the marrow, producing abnormal white cells that crowd out healthy blood production. It spans acute forms requiring urgent treatment and chronic forms managed over years with targeted drugs.

China’s hematology centers treat very large leukemia populations with full diagnostic platforms, induction protocols and transplant programs, alongside domestically developed targeted agents for specific mutations.

Symptoms & Signs

Fatigue, weakness and pallor from anemia

Fever and recurrent infections from neutropenia

Easy bruising, gum or nose bleeding from low platelets

Bone or joint pain from marrow expansion

Weight loss, night sweats and loss of appetite

Some chronic leukemias are discovered on routine blood counts long before symptoms

Diagnosis

Complete blood count with differential revealing abnormal cells or counts

Bone marrow aspiration and biopsy with morphology and flow cytometry

Cytogenetics and molecular testing — BCR-ABL, PML-RARA, FLT3, NPM1 and more — guiding precise classification

Next-generation sequencing panels detecting actionable mutations

Lumbar puncture checking for central-nervous-system involvement in acute leukemia

HLA typing performed early in case transplant becomes necessary

Treatment Options

Induction chemotherapy aiming for complete remission in acute leukemia

Targeted therapy: tyrosine-kinase inhibitors for CML and Ph+ ALL, all-trans retinoic acid with arsenic for APL

Consolidation and maintenance chemotherapy courses

Allogeneic hematopoietic stem-cell transplantation for high-risk or relapsed disease

Immunotherapy including CAR-T for B-cell acute lymphoblastic leukemia

Supportive care: transfusion, infection management and tumor-lysis prevention

Advanced Technologies & Novel Drug

Next-generation sequencing and flow cytometry minimal-residual-disease monitoring

Domestically developed FLT3 and BCL-2 inhibitor-class agents

Haplotype-identical transplant protocols pioneered at Chinese transplant centers

CAR-T programs for relapsed refractory B-ALL

Novel targeted agents for mutated AML and post-transplant maintenance

Hospital & Specialist

Return to Home